Consensus forecasts peg Q1 revenue at $11.84 billion and EPS at $0.87, as the stock trades at $164.20 against an average analyst target of $188.50. Investors are primarily focused on Wegovy sales figures and updates regarding the company's manufacturing capacity to meet massive global demand.
The obesity drug market remains the primary growth engine, with analysts watching for margin expansion following recent facility acquisitions. Continued competition from Eli Lilly’s Zepbound is also a critical factor for market share stability as Novo Nordisk defends its leadership position.